AstraZeneca to build its largest facility EVER with $50B investment in Virginia

On Monday, Governor Glenn Youngkin announced that AstraZeneca, a global biopharmaceutical company, has selected Virginia for its newest facility as part of the company's plan to invest $50 billion in the United States by 2030, according to a press release.

The drug substance manufacturing facility will leverage "AI, automation, and data analytics to optimise production, particularly in oncology, cardiovascular, renal, metabolism, respiratory, immunology, and rare diseases," the press release states. AstraZeneca did not disclose the exact location of the facility, but noted that it will be the company's largest single manufacturing investment in history.

"Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally," said Pascal Soriot, CEO of AstraZeneca. "It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines."
 

AstraZeneca, based in the United Kingdom, sells pharmaceuticals in over 125 countries, serving millions of people worldwide.

Governor Youngkin, a Republican, welcomed the company's "transformational investment" in the Commonwealth of Virginia, writing in the press release, "This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain."

"Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth," said Youngkin.

According to AstraZeneca, the US expansion will enable the company to meet its five-year target of producing half of its annual revenue in the United States. The corporation currently employs over 18,000 people in the United States and operates 19 R&D and manufacturing centers in America, WTOP News reported.

The US expansion comes as President Trump threatened to enact high tariffs on large pharmaceutical corporations, urging such companies to commit to manufacturing and research in the United States or risk penalties. Several additional pharmaceutical companies, such as Novartis, Sanofi, Roche, and Johnson & Johnson, have also declared their intention to expand in the US.